Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT05594342

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
The Young Investigator Group of Cardiovascular Research (from the registry)
Registry
  • NCT NCT05594342
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05594342. Randomized; no masking; primary purpose treatment. Start 2022-07-01 (actual); primary completion 2023-01-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
Acronym
IVA-CS
Condition
Heart Failure
Condition
Cardiogenic Shock
Condition
Ischemic Heart Disease
Intervention (Drug)
Ivabradine 7.5Mg Tab
Intervention (Drug)
DOBUTamine Injectable Solution
Lead sponsor
The Young Investigator Group of Cardiovascular Research (class: research network)

Record details

Record id
cardio:ct-nct05594342
Content hash
f4dd73cf40468fc84a1a0efecb59e904eaed91b4f761a5aedbcd090813594629